John Markels

CIK: 0001803424

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

PCVX

Vaxcyte, Inc.

Director

ARCT

Arcturus Therapeutics Holdings Inc.

Director

SGMO

SANGAMO THERAPEUTICS, INC

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

PCVX
Vaxcyte, Inc.
Jul 16, 2026
Award(A)
Stock Option (right to buy)
Direct
23K shares-
ARCT
Arcturus Therapeutics Holdings Inc.
Jun 5, 2026
Award(A)
Stock option (right to buy)
Direct
15K shares-
SGMO
SANGAMO THERAPEUTICS, INC
Jun 12, 2025
Award(A)
Direct
25K shares-
ARCT
Arcturus Therapeutics Holdings Inc.
Jun 9, 2025
Award(A)
Stock option (right to buy)
Direct
15K shares-

		Type	Shares	Price		Ownership
Jul 16, 2026	PCVX Vaxcyte, Inc.	Award(A) Stock Option (right to buy)	23,029	-	-	Direct
Jun 5, 2026	ARCT Arcturus Therapeutics Holdings Inc.	Award(A) Stock option (right to buy)	15,000	-	-	Direct
Jun 12, 2025	SGMO SANGAMO THERAPEUTICS, INC	Award(A)	25,000	-	-	Direct
Jun 9, 2025	ARCT Arcturus Therapeutics Holdings Inc.	Award(A) Stock option (right to buy)	15,000	-	-	Direct

1-4 of 4 transactions

About Markels John

Markels John (SEC CIK 0001803424) files insider reports with the SEC as Director of Vaxcyte, Inc. (PCVX), Director of Arcturus Therapeutics Holdings Inc. (ARCT) and Director of SANGAMO THERAPEUTICS, INC (SGMO).

Signal8 holds 5 ownership filings by Markels John (1 Form 3, 4 Form 4), filed between Jun 11, 2025 and Jul 16, 2026. Those filings report 4 transactions, from Jun 9, 2025 to Jul 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Markels John's filings is in SAN CARLOS, CA.

Recent filings by Markels John

Jul 16, 2026: Grant or award of PCVX derivative securities (Form 4, code A).
Jun 5, 2026: Grant or award of ARCT derivative securities (Form 4, code A).
Jun 12, 2025: Grant or award of SGMO shares (Form 4, code A).
Jun 9, 2025: Grant or award of ARCT derivative securities (Form 4, code A).

Other insiders filing for Vaxcyte, Inc. (PCVX)

Wassil Jim, EVP, Chief Scientific Ofc, COO
Cowan Elvia, SVP, Finance & CAO
PICKERING GRANT, CHIEF EXECUTIVE OFFICER
GUGGENHIME ANDREW, PRESIDENT AND CFO
Dhaliwal Harpreet S., Chief Technical Ops Officer
Jodar Luis, Chief Medical Officer

How to read Form 4 transaction codes